Targeting Human Central Nervous System Protein Kinases: An Isoform Selective p38αMAPK Inhibitor That Attenuates Disease Progression in Alzheimer's Disease Mouse Models

ACS Chemical Neuroscience

Volumn 6, Issue 4, 2015, Pages 666-680

  Roy, Saktimayee M ^a   Grum Tokars, Valerie L ^a   Schavocky, James P ^a   Saeed, Faisal ^b   Staniszewski, Agnieszka ^b   Teich, Andrew F ^b   Arancio, Ottavio ^b   Bachstetter, Adam D ^c   Webster, Scott J ^c   Van Eldik, Linda J ^c   Minasov, George ^a   Anderson, Wayne F ^a   Pelletier, Jeffrey C ^a   Watterson, D Martin ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Columbia University ^*  (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

chemical synthesis; cognitive dysfunction; crystallography; pharmacology; protein kinase; Signal transduction

Indexed keywords

6 (4 METHYLPIPERAZIN 1 YL) 3 (NAPHTHALEN 2 YL) 4 (PYRIDIN 4 YL)PYRIDAZINE; GUANOSINE PHOSPHATE; ISOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PROTEIN KINASE; UNCLASSIFIED DRUG; NEUROPROTECTIVE AGENT; PROTEIN KINASE INHIBITOR;

ALZHEIMER DISEASE; AMNESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; BRAIN NERVE CELL; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; GLIA; HIPPOCAMPUS; MALE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RAT; SPATIAL MEMORY; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; HUMAN; LEARNING; LIVER MICROSOME; MEMORY DISORDERS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PRECLINICAL STUDY; PSYCHOLOGY; SPRAGUE DAWLEY RAT; SYNAPSE; SYNTHESIS; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; ANIMALS; ASSOCIATION LEARNING; CELL LINE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; HUMANS; MALE; MEMORY DISORDERS; MICE, TRANSGENIC; MICROSOMES, LIVER; MITOGEN-ACTIVATED PROTEIN KINASE 14; MOLECULAR STRUCTURE; NEUROPROTECTIVE AGENTS; PROTEIN KINASE INHIBITORS; RATS, SPRAGUE-DAWLEY; SPATIAL MEMORY; SYNAPSES;

EID: 84927920792     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/acschemneuro.5b00002     Document Type: Article

References (34)

1. U.S. Food and Drug Administration (2001) Novartis, NDA 021335.
2. Fabbro, D., Cowan-Jacob, S. W., Mobitz, H., and Martiny-Baron, G. (2012) Targeting cancer with small-molecular-weight kinase inhibitors. In Methods in Molecular Biology (Walker, J. M., Ed.), 1st ed., Vol. 795, pp 1 - 34, Humana Press, New York.
3. Rask-Andersen, M., Zhang, J., Fabbro, D., and Schiöth, H. B. (2014) Advances in kinase targeting: current clinical use and clinical trials Trends Pharmacol. Sci. 35, 604 - 620
4. O'Brien, Z. and Moghaddam, M. F. (2013) Small Molecule Kinase Inhibitors Approved by the FDA from 2000 to 2011: A Systematic review of preclinical ADME Data Expert Opin. Drug Metabol. Toxicol. 9, 1597 - 1612
5. Uitdehaag, J. C., Verkaar, F., Alwan, H., de Man, J., Buijsman, R. C., and Zaman, G. J. R. (2012) A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets Br. J. Pharmacol. 166, 858 - 876
6. Watterson, D. M., Grum-Tokars, V. L., Roy, S. M., Schavocky, J. P., Bradaric, B. D., Bachstetter, A. D., Xing, B., Dimayuga, E., Saeed, F., Zhang, H., Staniszewski, A., Pelletier, J. C., Minasov, G., Anderson, W. F., Arancio, O., and Van Eldik, L. J. (2013) Development of novel in vivo chemical probes to address CNS protein kinase involvement in synaptic dysfunction PLoS One 8, e66226
7. Pardridge, W. M. (2005) Blood-brain barrier: Bottleneck in brain drug development NeuroRx 2, 3 - 14
8. Munoz, L. and Ammit, A. J. (2010) Targeting p38 MAPK pathway for the treatment of Alzheimer's disease Neuropharmacology 58, 561 - 568
9. Bachstetter, A. D., Watterson, D. M., and Van Eldik, L. J. (2014) Target engagement analysis and link to pharmacodynamics endpoint for a novel class of CNS-penetrant and efficacious p38α MAPK inhibitors J. Neuroimmune Pharmacol. 9, 454 - 460
10. Chavkin, C., Schattauer, S. S., and Levin, J. R. (2014) Arrestin-Mediated Activation of p38 MAPK: molecular mechanism and behavioral consequences. In Handbook of Experimental Pharmacology (Berlin, W. R., Ed), 1st ed, Vol. 219, pp 281 - 292, Springer Press, New York.
11. Berg, J. M., Rogers, M. E., and Lyster, P. M. (2010) Systems biology and pharmacology Clin. Pharmacol. Ther. 88, 17 - 19
12. Munoz, L., Ralay Ranaivo, H., Roy, S. M., Hu, W., Craft, J. M., McNamara, L. K., Wing Chico, L., Van Eldik, L. J., and Watterson, D. M. (2007) A novel p38α MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model J. Neuroinflammation 4, 21
13. Tong, L., Prieto, G. A., Kramar, E. A., Smith, E. D., Cribbs, D. H., Lynch, G., and Cotman, C. W. (2012) Brain-derived neurotropic factor-dependent synaptic plasticity is suppressed by interleukin-1β via p38 mitogen-activated protein kinase J. Neurosci. 32, 17714 - 17724
14. Duma, R. S. and Aghajanian, G. K. (2012) Synaptic dysfunction in depression: potential therapeutic targets Science 338, 68 - 72
15. Picconi, B., Piccoli, G., and Calabresi, P. (2012) Synaptic dysfunction in Parkinson's disease Adv. Exp. Med. Biol. 970, 553 - 572
16. Correa, S. A. and Eales, K. L. (2012) The role of p38 MAPK and its substrates in neuronal plasticity and neurodegenerative disease J. Signal Transduction 2012, 649079
17. Zhu, C. B., Steiner, J. A., Munn, J. L., Daws, L. C., Hewlett, W. A., and Blakely, R. D. (2007) Rapid stimulation of presynaptic serotonin transport by A (3) adenosine receptors J. Pharmacol. Exp. Ther. 322, 332 - 340
18. Samuvel, D. J., Jayanthi, L. D., Bhat, N. R., and Ramamoorthy, S. (2005) A role for p38 mitogen-activated protein kinase in the regulation of the serotonin transporter: Evidence for distinct cellular mechanisms involved in transporter surface expression J. Neurosci. 25, 29 - 41
19. Bruchas, M. R., Schindler, A. G., Shankar, H., Messinger, D. I., Miyatake, M., Land, B. B., Lemos, J. C., Hagan, C. E., Neumaier, J. F., Quintana, A., Palmiter, R. D., and Chavkin, C. (2011) Selective p38a MAPK Deletion in Serotonergic Neurons Produces Stress Resilience in Models of Depression and Addiction Neuron 71, 498 - 511
20. Zhan, L., Xie, Q., and Tibbetts, R. S. (2015) Opposing roles of p38 and JNK in a Drosophila model of TDP-43 proteinopathy reveal oxidative stress and innate immunity as pathogenic components of neurodegeneration Hum. Mol. Genet. 24, 757 - 772
21. Zhu, C. B., Hewlett, W. A., Feoktistov, I., Biaggioni, I., and Blakely, R. D. (2004) Adenosine receptor, protein kinase G, and p38 mitogen-activated protein kinase-dependent up-regulation of serotonin transporters involves both transporter trafficking and activation Mol. Pharmacol. 65, 1462 - 1474
22. Zhu, C. B., Carneiro, A. M., Dostmann, W. R., Hewlett, W. A., and Blakely, R. D. (2005) p38 MAPK activation elevates serotonin transport activity via a trafficking-independent, protein phosphatase 2A-dependent process J. Biol. Chem. 280, 15649 - 15658
23. Morfini, G. A., Bosco, D. A., Brown, H., Gatto, R., Kaminska, A., Song, Y., Molla, L., Baker, L., Marangoni, M. N., Berth, S., Tavassoli, E., Bagnato, C., Tiwari, A., Hayward, L. J., Pigino, G. F., Watterson, D. M., Huang, C.-F., Banker, G., Brown, R. H., Jr., and Brady, S. T. (2013) Inhibition of Fast Axonal Transport by Oathogenic SOD1 involves Activation of p38 MAP Kinase PLoS One 8, e65235
24. Hu, W., Ralay Ranaivo, H., Roy, S. M., Behanna, H. A., Wing, L. K., Munoz, L., Guo, L., Van Eldik, L. J., and Watterson, D. M. (2007) Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits Bioorg. Med. Chem. Lett. 17, 414 - 418
25. Chico, L. K., Van Eldik, L. J., and Watterson, D. M. (2009) Targeting protein kinases in central nervous system disorders Nat. Rev. Drug Discovery 8, 892 - 909
26. Chico, L. K., Behanna, H. A., Hu, W., Zhong, G., Roy, S. M., and Watterson, D. M. (2009) Molecular properties and CYP2D6 substrates: central nervous system therapeutics case study and pattern analysis of a substrate database Drug Metab. Dispos. 37, 2204 - 2211
27. Bachstetter, A. D., Norris, C. M., Sompol, P., Wilcock, D. M., Goulding, D., Neltner, J. H., St. Clair, D., Watterson, D. M., and Van Eldik, L. J. (2012) Early stage drug treatment that normalizes proinflammatory cytokine production attenuates synaptic dysfunction in a mouse model that exhibits age-dependent progression of Alzheimer's disease-related pathology J. Neurosci. 32, 10201 - 10210
28. U.S. Food and Drug Administration (2008) Guidance for industry Q3A Impurities in New Drug substances, U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER), www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm073385.pdf.
29. Reynolds, C. H. (2014) Protein-Ligand Cocrystal Structures: We Can Do Better ACS Med. Chem. Lett. 5, 727 - 729
30. U.S. Food and Drug Administration (2001) Guidance for Industry S7A Safety Pharmacology Studies for human Pharmaceuticals. U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER), www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm074959.pdf.
31. Wilcock, D. M. and Colton, C. A. (2009) Immunotherapy, vascular pathology and microhemorrhages in transgenic mice CNS Neurol. Disord.: Drug Targets 8, 50 - 64
32. Li, L., Li, G., Yu, C., and Li, Y. (2013) A meta-analysis of the role of p38 mitogen-activated protein kinase inhibitors in patients with active rheumatoid arthritis Clin. Rheumatol. 32, 1697 - 1702
33. Newby, L. K., Marber, M. S., Melloni, C., Sarov-Blat, L., Aberle, L. H., Aylward, P. E., Cai, G., de Winter, R. J., Hamm, C. W., Heitner, J. F., Kim, R., Lerman, A., Patel, M. R., Tanguay, J. F., Lepore, J. J., Al-Khalidi, H. R., Sprecher, D. L., and Granger, C. B., et al. 2014, Losmapimod, a novel p38 mitogen-activated protein kinase inhibitors, innon-ST-segment elevation myocardial infection: a randomized phase 2 trial J.-Lancet 384, 1187 - 1195
34. Avdeef, A., Comer, J. E. A., and Thomson, S. J. (1993) pH-metric logP. 3. Glass electrode calibration in methanol-water, applied to pKa determination of water-insoluble substances Anal. Chem. 65, 42 - 49